Insider Selling: Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells $230,848.54 in Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) EVP Ryan Savitz sold 2,561 shares of the business’s stock in a transaction that occurred on Tuesday, November 10th. The stock was sold at an average price of $90.14, for a total value of $230,848.54. Following the completion of the transaction, the executive vice president directly owned 29,276 shares in the company, valued at $2,638,938.64. The trade was a 8.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Ryan Savitz also recently made the following trade(s):

• On Wednesday, November 11th, Ryan Savitz sold 3,044 shares of Dianthus Therapeutics stock. The shares were sold at an average price of $90.03, for a total value of $274,051.32.
• On Thursday, November 12th, Ryan Savitz sold 17,724 shares of Dianthus Therapeutics stock. The shares were sold at an average price of $90.56, for a total value of $1,605,085.44.
• On Monday, November 9th, Ryan Savitz sold 100,713 shares of Dianthus Therapeutics stock. The shares were sold at an average price of $90.54, for a total value of $9,118,555.02.

Dianthus Therapeutics Stock Down 0.7%

DNTH traded down $0.67 during trading on Friday, hitting $91.81. The company’s stock had a trading volume of 681,515 shares, compared to its average volume of 942,202. The stock has a market capitalization of $5.17 billion, a price-to-earnings ratio of -23.01 and a beta of 1.47. The firm’s 50 day moving average price is $88.45 and its two-hundred day moving average price is $86.56. Dianthus Therapeutics, Inc. has a 12 month low of $34.29 and a 12 month high of $117.88.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Wednesday, November 4th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.94) by $0.13. Dianthus Therapeutics had a negative return on equity of 19.68% and a negative net margin of 7,436.50%. The company had revenue of $1.21 million for the quarter, compared to analysts’ expectations of $0.46 million. On average, sell-side analysts forecast that Dianthus Therapeutics, Inc. will post -3.55 earnings per share for the current year.

Recent Dianthus Therapeutics Headlines

Here are a few of the latest headlines about DNTH:

• Positive Sentiment: Analyst coverage is broadly favorable. A report highlights bullish views on DNTH, and HC Wainwright reiterated a Buy rating with a $158 price target and a bullish FY2026 earnings outlook. The available FY2026 report does not detail the estimate or its rationale. Article: Analysts Are Bullish on These Healthcare Stocks Article: HC Wainwright Has Bullish Estimate for DNTH FY2026 Earnings
• Negative Sentiment: EVP Ryan Savitz sold 124,042 shares from November 9–12 for about $11.2 million, sharply reducing his reported stake. The filings do not state why he sold, but the scale of the transactions may concern investors. Article: Dianthus Therapeutics EVP Sells Shares

Analyst Upgrades and Downgrades

DNTH has been the topic of a number of research analyst reports. Wedbush increased their price objective on shares of Dianthus Therapeutics from $105.00 to $122.00 and gave the stock an “outperform” rating in a report on Wednesday, August 5th. Citigroup assumed coverage on shares of Dianthus Therapeutics in a research report on Friday, September 4th. They issued a “buy” rating and a $156.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Thursday, October 15th. Truist Financial upped their target price on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Finally, Roth Capital initiated coverage on shares of Dianthus Therapeutics in a research report on Tuesday, October 27th. They set a “buy” rating and a $113.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $128.77.

Institutional Investors Weigh In On Dianthus Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. 49 Wealth Management LLC acquired a new position in shares of Dianthus Therapeutics during the third quarter valued at $212,000. First Trust Advisors LP boosted its holdings in Dianthus Therapeutics by 42.1% in the third quarter. First Trust Advisors LP now owns 133,810 shares of the company’s stock valued at $11,782,000 after acquiring an additional 39,658 shares during the last quarter. IFG Advisory LLC boosted its holdings in Dianthus Therapeutics by 19.1% in the third quarter. IFG Advisory LLC now owns 6,000 shares of the company’s stock valued at $528,000 after acquiring an additional 961 shares during the last quarter. Fisher Asset Management LLC increased its position in Dianthus Therapeutics by 1,068.4% in the third quarter. Fisher Asset Management LLC now owns 272,863 shares of the company’s stock worth $24,026,000 after purchasing an additional 249,510 shares during the period. Finally, Fifth Third Bancorp increased its position in Dianthus Therapeutics by 23.6% in the third quarter. Fifth Third Bancorp now owns 676 shares of the company’s stock worth $60,000 after purchasing an additional 129 shares during the period. 47.53% of the stock is owned by institutional investors and hedge funds.

About Dianthus Therapeutics

Dianthus Therapeutics is a clinical-stage biotechnology company developing medicines for autoimmune and inflammatory diseases involving the complement system, a part of the immune system. The company’s research focuses on selectively targeting complement activity that contributes to disease. Dianthus became a publicly traded company in 2023 through a merger with Magenta Therapeutics. Its clinical development activities are intended to support potential use across patient populations, though the company has not established a commercial geographic footprint.